Zobrazeno 1 - 10
of 13
pro vyhledávání: '"C.J.A. Punt"'
Autor:
T. van der Straaten, H-J Guchelaar, J. Houwing-Duistermaat, Y. Ariyurek, H. Gelderblom, C.J.A. Punt, Jan Pander, Stefan Böhringer
Publikováno v:
Journal of Clinical Oncology. 29:3609-3609
3609 Background: A more optimal selection of patients that will benefit from the frequently used first-line treatment of advanced colorectal cancer (ACC) consisting of the combination of capecitabi...
Autor:
Andrew D. Vincent, C.J.A. Punt, Artur M. Burylo, H-J Guchelaar, Annemieke Cats, J.H.M. Schellens, Jolien Tol, Maarten J. Deenen, A. G. E. M. de Boer, J. H. Beijnen
Publikováno v:
Journal of Clinical Oncology. 28:3099-3099
3099 Background: Capecitabine is the oral prodrug of 5-FU, which is inactivated for 85% by dihydropyrimidine dehydrogenase (DPD, DPYD). The aim of this study was to determine the effect of DPYD SNP...
Autor:
W.T.A. van der Graaf, C.J.A. Punt, J. Doornebal, Johanna N. H. Timmer-Bonte, M. Koopman, A.N.M. Wymenga, Ninja Antonini
Publikováno v:
Journal of Clinical Oncology. 27:9542-9542
9542 Background: Although older pts have been underrepresented in clinical trials, studies support the efficacy of chemotherapy in older pts with aCRC. We retrospectively evaluated efficacy, tolerability, and quality of life (QoL, EORTC QLQ C30) of o
Publikováno v:
Journal of Clinical Oncology. 26:11042-11042
11042 Background: The excision repair cross-complementing (ERCC) gene family prevents damage to DNA caused by nucleotide excision and repair. The expression of ERCC1 mRNA is related to resistance to platinum compounds. The aim of this study was to in
Autor:
A. Vos, Jolien Tol, Geert-Jan Creemers, Ninja Antonini, Linda Mol, Frans L. G. Erdkamp, J. G. Schrama, C.J.A. Punt, C. J. Rodenburg, Annemieke Cats
Publikováno v:
Journal of Clinical Oncology. 26:LBA4011-LBA4011
LBA4011 Background: Cetuximab, a chimaeric monoclonal antibody against the epidermal growth factor receptor (EGFR) has shown efficacy in patients (pts) with ACC. Preclinical and early clinical studies suggest a benefit for combining VEGF and EGFR tar
Autor:
Sandrine Marreaud, R. Belli, Arend Heerschap, C.M.L. van Herpen, C.J.A. Punt, Claudio Bordignon, H.W.M. van Laarhoven, Walter Fiedler, S. van Asten, Ingrid M.E. Desar
Publikováno v:
Journal of Clinical Oncology. 26:3521-3521
3521 Background: NGR-TNF is a novel agent exploiting a tumor homing peptide (cNGRCG) that selectively targets CD13 that is expressed on tumor neovasculature. Preclinical data show that its antitumor activity is achieved by a change of vascular permea
Autor:
H. Gelderblom, Henk-Jan Guchelaar, R. J. van der Straaten, J. Pander, Jolien Tol, C.J.A. Punt, Ninja Antonini
Publikováno v:
Journal of Clinical Oncology. 26:2574-2574
2574 Background: In the CAIRO2 study the addition of Cet to the combination Cap, Ox and Bev for patients with untreated ACC is investigated. The aim of this side study is to evaluate predictive PGx...
Autor:
C.J.A. Punt, Aafke H. Honkoop, Linda Mol, Frans L. G. Erdkamp, Miriam Koopman, J. Douma, Ninja Antonini, J. Wals, R.S. de Jong, C. J. Rodenburg
Publikováno v:
Journal of Clinical Oncology. 25:4012-4012
4012 Background: Overall survival (OS) in phase III studies with 1st line combination therapy in ACC may be influenced by imbalances in salvage treatments. This is the first study that prospectively investigates the sequential vs the combined use of
Autor:
M. Koopman, J.H.J.M. van Krieken, Linda Mol, G A M Kortman, Ninja Antonini, Nicoline Hoogerbrugge, Leonie J. M. Mekenkamp, M.J.L. Ligtenberg, C.J.A. Punt
Publikováno v:
Journal of Clinical Oncology. 25:4118-4118
4118 Background: Microsatellite instability (MSI) is present in 10–20% of patients (pts) with non-hereditary colorectal cancer (CRC) and is generally associated with improved overall survival. The effect of chemotherapy in such pts is uncertain, an
Autor:
Owain Saunders, Ute Zirrgiebel, H. van Cruijsen, Emile E. Voest, Jane Robertson, C.M.L. van Herpen, J. Drevs, Clemens Unger, C.J.A. Punt, G. Giaccone
Publikováno v:
Journal of Clinical Oncology. 25:3560-3560
3560 Background: Antiangiogenic agents have recently demonstrated promising activity in patients with advanced RCC. AZD2171 is an oral, highly potent and selective inhibitor of VEGFR-1, -2 and -3 tyrosine kinases, and is currently in Phase II/III dev